NGENLA Market Summary

Key Factors Driving NGENLA Growth

1. Once-weekly dosing is a major commercial differentiator: NGENLA is a long-acting recombinant human growth hormone designed to replace daily GH injections with one subcutaneous injection per week. The reduced injection burden can be particularly valuable for children who may require several years of treatment. Pfizer's Phase III program demonstrated that weekly NGENLA was non-inferior to daily somatropin for annualized height velocity, supporting its use as a convenient alternative to established daily GH therapy.

2. Clinical efficacy comparable with daily somatropin supports adoption: In the pivotal Phase III trial involving 224 prepubertal children with GHD, NGENLA produced an annualized height velocity of 10.1 cm/year versus 9.8 cm/year with daily somatropin at Week 52, with a treatment difference of 0.3 cm/year (95% CI: −0.2 to 0.9). Longer-term extension data are also encouraging: among 91 children treated for at least two years, the mean cumulative improvement in height SDS from baseline was 1.38. These results provide evidence for sustained growth response rather than relying solely on the convenience benefit of weekly administration.

3. Broad international regulatory footprint creates a large commercial base: NGENLA has obtained regulatory approval for pediatric GHD in more than 50 markets, including the US, EU, Japan, Canada and Australia. The U.S. FDA approved NGENLA in June 2023 for children 3 years and older with growth failure caused by inadequate endogenous GH secretion. This broad geographic availability gives Pfizer a substantial opportunity to increase penetration as reimbursement, physician familiarity and patient access improve across individual markets.

4. Increasing commercial traction is translating into higher partner revenue: OPKO's financial results provide a useful indicator of NGENLA's commercial progress because Pfizer commercializes the product while OPKO receives a tiered gross-profit share. OPKO reported $31.9 million in 2025 royalty and gross-profit-share revenue from NGENLA and Genotropin combined. More specifically, NGENLA-related gross-profit-share payments were $12.5 million in Q4 2025, compared with $9.6 million in Q4 2024, indicating stronger global commercial performance. OPKO explicitly attributed the increase to Pfizer's global commercial progress with NGENLA.

5. Expansion of the eligible pediatric population represents an important future catalyst: NGENLA is currently approved for pediatric GHD, but OPKO and Pfizer are pursuing opportunities to expand the product into additional indications, including children born small for gestational age (SGA). OPKO's 2025 10-K states that the company is supporting Pfizer's efforts to pursue additional indications such as SGA; approval in this population would broaden the addressable patient pool and could generate an additional $50 million milestone payment to OPKO under its Pfizer agreement.

NGENLA Recent Developments

In July 2024, OPKO Health announced a USD 250 million financing deal secured against its regional profit share payments from Pfizer. This structure allows OPKO to retain immediate capital while maintaining full eligibility for up to USD 100 million in remaining milestone payments from Pfizer.

“NGENLA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of NGENLA for approved indication like Somatotropin deficiency in the 7MM. A detailed picture of NGENLA’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the NGENLA for approved indications. The NGENLA market report provides insights about NGENLA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current NGENLA performance, future market assessments inclusive of the NGENLA market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of NGENLA sales forecasts, along with factors driving its market.

NGENLA Drug Summary

NGENLA is a long-acting recombinant human growth hormone (rhGH) therapy developed by Pfizer for the treatment of growth failure in pediatric patients with growth hormone deficiency. It is a modified form of recombinant human growth hormone in which three copies of the C-terminal peptide (CTP) of human chorionic gonadotropin are fused to the growth hormone molecule, extending its half-life and enabling once-weekly subcutaneous administration compared with conventional daily growth hormone injections. Following administration, somatrogon binds to growth hormone receptors and stimulates the production of insulin-like growth factor-1 (IGF-1), promoting longitudinal bone growth and supporting protein, carbohydrate, and lipid metabolism. NGENLA is approved in the United States for the treatment of pediatric patients aged 3 years and older with growth failure due to inadequate secretion of endogenous growth hormone, with approvals also granted in other markets for pediatric growth hormone deficiency. The drug is administered once weekly using a prefilled pen, with dosing individualized according to body weight and clinical response. By reducing injection frequency from daily to weekly while maintaining the biological activity of growth hormone, NGENLA provides a potentially more convenient treatment option for children requiring long-term growth hormone replacement and may help address adherence challenges associated with daily injectable therapy. The report provides NGENLA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the NGENLA Market Report

The report provides insights into:

• A comprehensive product overview including the NGENLA MoA, description, dosage and administration, research and development activities in approved indication like Somatotropin deficiency.
• Elaborated details on NGENLA regulatory milestones and other development activities have been provided in NGENLA market report.
• The report also highlights NGENLA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The NGENLA market report also covers the patents information, generic entry and impact on cost cut.
• The NGENLA market report contains current and forecasted NGENLA sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The NGENLA market report also features the SWOT analysis with analyst views for NGENLA in approved indications.

Methodology

The NGENLA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NGENLA Analytical Perspective by DelveInsight

• In-depth NGENLA Market Assessment

This NGENLA sales market forecast report provides a detailed market assessment of NGENLA for approved indication like Somatotropin deficiency in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted NGENLA sales data uptil 2034.

• NGENLA Clinical Assessment

The NGENLA market report provides the clinical trials information of NGENLA for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

NGENLA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

NGENLA Market Potential & Revenue Forecast

• Projected market size for the NGENLA and its key indications
• Estimated NGENLA sales potential (NGENLA peak sales forecasts)
• NGENLA Pricing strategies and reimbursement landscape

NGENLA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• NGENLA Market positioning compared to existing treatments
• NGENLA Strengths & weaknesses relative to competitors

NGENLA Regulatory & Commercial Milestones

• NGENLA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

NGENLA Clinical Differentiation

• NGENLA Efficacy & safety advantages over existing drugs
• NGENLA Unique selling points

NGENLA Market Report Highlights

• In the coming years, the NGENLA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The NGENLA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NGENLA’s dominance.
• Other emerging products for Somatotropin deficiency are expected to give tough market competition to NGENLA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NGENLA in approved indications.
• Analyse NGENLA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted NGENLA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of NGENLA in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of NGENLA? How strong is NGENLA’s clinical and commercial performance?
• What is NGENLA’s clinical trial status in each individual indications such as Somatotropin deficiency and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NGENLA Manufacturers?
• What are the key designations that have been granted to NGENLA for approved indications? How are they going to impact NGENLA’s penetration in various geographies?
• What is the current and forecasted NGENLA market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of NGENLA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to NGENLA for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is NGENLA? What is the duration of therapy and what are the geographical variations in cost per patient?